Results 121 to 130 of about 69,966 (266)

Lactate‐Primed NETosis Modulates Hepatic Regeneration During Acute Liver Failure via the TLR9/KLF15/AJUBA Axis

Cell Proliferation, EarlyView.
This study elucidates a novel Kupffer cell‐neutrophil‐hepatocyte axis that drives metabolic‐immune crosstalk during acute liver failure. Specifically, lactate‐primed NETs release links metabolic reprogramming to NETosis‐induced regenerative failure in hepatocytes via the TLR9/KLF15/AJUBA axis.
Jin Guo, Xiaoya Zhang, Danmei Zhang, Chunxia Shi, Luwen Wang, Zuojiong Gong   +5 more
wiley   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso, Maria Francesca Mansueto, Cristina Santoro, Rita Carlotta Santoro, Luigi Piero Solimeno, Annarita Tagliaferri, Ezio Zanon, Isabella Garagiola, Flora Peyvandi   +19 more
wiley   +1 more source

Chronic HBV patients divided into three groups based on HBV DNA and HBeAg levels.

, 2014
HBeAg levels, HBsAg levels and HBV DNA were measured in 45 chronic HBV patients. (A) HBV patients were divided into an HBeAgnegative/HBeAglow group (100 IU/ml).
Zwier M. Groothuismink (563332), André Boonstra (121511), Gertine W. van Oord (563333), Andrea M. Woltman (357972), Arjan Boltjes (563331), Harry L. A. Janssen (121505)   +5 more
core   +1 more source

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source

Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study

Hepatology Research, EarlyView.
ABSTRACT Aim Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major causes of liver‐related morbidity and mortality worldwide. Although Japan has implemented nationwide screening and treatment programs for decades, updated nationwide estimates and long‐term projections are limited.
Junko Tanaka, Akemi Kurisu, Ko Ko, Aya Sugiyama, Tomoyuki Akita   +4 more
wiley   +1 more source

Point Prevalence of Hepatitis B Virus Infection among Adolescents in Visakhapatnam, India

Journal of Medical Microbiology and Infectious Diseases, 2015
Introduction: Occurrence of detectable amounts of viral antigen or viral particles in the blood of infected patients with Hepatitis B virus (HBV) is a significant characteristic of HBV infection. Detection of HBV antigen or its DNA among individuals of a
Vijayalakshmi Payala, Sreedevi Hanumantha, Pilli Hema Prakash Kumari   +2 more
doaj  

Hepatitis B Virus Infection Status in Japanese Children Prior to Universal Vaccination: Sustained Effectiveness of Mother‐to‐Child Transmission Prevention and Residual Infection Burden

Hepatology Research, EarlyView.
ABSTRACT Aim To evaluate the effectiveness of prevention of mother‐to‐child transmission (PMTCT) over 25 years, we conducted a nationwide epidemiological survey through a comprehensive assessment of hepatitis B virus (HBV) markers. Methods Two cohorts were recruited before universal vaccination: children aged 9–10 years undergoing school health ...
Aiko Sakai, Yasuhito Tanaka, Hiroshi Yotsuyanagi, Masaya Sugiyama, Ichiro Morioka, Kiyotaka Kosugiyama, Kimiaki Uetake, Tomohiro Katsuta, Atsushi Imamura, Tomoko Takano, Hitoshi Tajiri, Akihito Ishida, Kosuke Ushijima, Yumiko Nakashima, Hiroyuki Moriuchi, Shinji Iwane, Kota Sawada, Yosuke Shimizu, Yukari Uemura, Manabu Tagawa, Masashi Mizokami, Ryo Sumazaki   +21 more
wiley   +1 more source

Mitochondrial D-loop mutations and deletion profiles of cancerous and noncancerous liver tissue in hepatitis B virus-infected liver

, 2005
The largest single underlying cause of hepatocellular carcinoma (HCC) worldwide is hepatitis B virus (HBV) infection. Hepatitis B virus increases cellular oxidative stress and the development of HCC occurs after a long latency period.
J A Ross, Wheelhouse, Nicholas M, D J Harrison, Wigmore, S J, Lai, P B S, P B S Lai, Wheelhouse, N M, Ross, J A, Harrison, D J, N M Wheelhouse, S J Wigmore   +10 more
core   +1 more source

Efficacy of dolutegravir/lamivudine in adults with HIV‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

HIV Medicine, EarlyView.
Abstract Objectives As two‐drug HIV‐1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti‐HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three‐ or four‐drug regimens (3DRs/4DRs ...
D. Fox, J. Slim, E. T. Overton, A. Doblado‐Maldonado, P. Jeffery, R. A. Grove, S. D. Advani, R. Borsi, C. M. Parry, M. Underwood, B. Jones   +10 more
wiley   +1 more source

Long‐Acting Cabotegravir/Rilpivirine Reduces Immune‐Activation and ‐Senescence in People With HIV With CMV Co‐Infection

Immunology, EarlyView.
This study investigates the impact of switching to long‐acting (LA) injectable cabotegravir and rilpivirine (CAB/RPV‐LA) on immune‐activation and ‐senescence in people with HIV (PWH). Thirty‐seven PWH switching to CAB/RPV‐LA and nine continuing oral ART were analysed over 72 weeks. LA therapy led to significant reductions in activation T and senescence
Mariasilvia Guardiani, Eeva Tortellini, Anna Carraro, Maria Antonella Zingaropoli, Lorenzo Ansaldo, Alessandra Grimaldi, Serena Vita, Federica Dominelli, Fabio Mengoni, Caterina Pasquazzi, Ombretta Turriziani, Maria Rosa Ciardi, Vincenzo Vullo, Claudio Maria Mastroianni, Raffaella Marocco, Cosmo Del Borgo, Miriam Lichtner   +16 more
wiley   +1 more source